✦ LIBER ✦

Randomized trial of high-dose epirubicin-cisplatin (HDEP) versus etoposide-cisplatin (EP) in small cell lung cancer (SCLC). Study retrospective in older patients

✍ Scribed by Camps, C; Artal, A; Gomez-Codina, J; Gonzalez-Larriba, J.L; Barneto, I; Carrato, A; Isla, D; Garcia-Girón, C; Font, A; Meana, A; Lomas, M; Vadell, C; Arrivi, A; Alonso, C; Maestu, I; Campbell, J; Rosell, R

Book ID: 118569679
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 136 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80134-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter randomized phase III study

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

✍ Mavroudis, D; Papadakis, E; Veslemes, M; Agelidou, M; Tsiafaki, X; Agelidou, G; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Etoposide-cisplatin (EP) versus four-dru

Etoposide-cisplatin (EP) versus four-drug combination etoposide-cisplatin-epirubicin-cyclophosphamide (PCDE) in extensive disease small cell lung cancer (ED-SCLC). A FNCLCC phase III multicentre study

✍ Pujol, J; Daures, J; Riviere, A; Quoix, E; Depierre, A; Breton, J.L; Lemarie, E; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Paclitaxel-cisplatin-etoposide (TEP) ver

Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial

✍ D. Mavroudis; E. Papadakis; M. Veslemes; M. Agelidou; M. Toubis; A. Agelidou; J. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Randomized, phase II study of topotecan/

Randomized, phase II study of topotecan/paclitaxel versus cisplatin/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC)

✍ H. Lena; J. Breton; W. Yu; K. Steppert; K. Lightcap; G. Ross; M. Lymboura 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Phase II feasibility study of high dose

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

✍ Rafael Rosell; Juan Carles; Albert Abad; Jose M. Jimeno; Isabel Moreno; Agustin 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 472 KB

O-156 Randomized, phase III trial compar

O-156 Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC)

✍ Langer, C.; Hanna, N.; Einhorn, L.; Sandler, A.; Ansari, R.; Ellis, P.; Byrne, M 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 278 KB